The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 04, 2021

Filed:

Feb. 23, 2017
Applicant:

Provecs Medical Gmbh, Hamburg, DE;

Inventors:

Frank Schnieders, Hamburg, DE;

Andrea Miegel, Hamburg, DE;

Carolin Biermann-Fleischhauer, Ahrensburg, DE;

Assignee:

Provecs Medical GmbH, Hamburg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); C12N 15/63 (2006.01); C07H 21/02 (2006.01); A61K 48/00 (2006.01); C12N 15/86 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/55 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A01K 67/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 48/0016 (2013.01); A61K 48/0075 (2013.01); A61K 48/0083 (2013.01); A61K 48/0091 (2013.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C07K 14/5434 (2013.01); C07K 14/55 (2013.01); C07K 14/70532 (2013.01); C07K 14/70575 (2013.01); C12N 15/86 (2013.01); C12N 2710/10043 (2013.01); C12N 2840/203 (2013.01); C12N 2840/206 (2013.01);
Abstract

Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5' to 3′ orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.


Find Patent Forward Citations

Loading…